Apellis Pharmaceuticals (APLS) News Today $18.01 -1.60 (-8.16%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Apellis Pharmaceuticals (NASDAQ:APLS) Sets New 1-Year Low - Time to Sell?Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 1-Year Low - Time to Sell?April 9 at 8:48 PM | marketbeat.comRhenman & Partners Asset Management AB Sells 171,909 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Rhenman & Partners Asset Management AB lessened its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 46.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 195,591 shares of the company's stockApril 7 at 6:23 AM | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Landscape Capital Management L.L.C.Landscape Capital Management L.L.C. grew its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 85.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 49,986 shares of the company's stock after purchasing an additional 23,086April 7 at 5:31 AM | marketbeat.comTrexquant Investment LP Takes $6.48 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Trexquant Investment LP purchased a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 203,008 sharesApril 7 at 4:37 AM | marketbeat.comNorges Bank Takes Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Norges Bank purchased a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,086,243 shares of the company's stock, valued at approximately $34,662,000. NorgApril 7 at 3:44 AM | marketbeat.comWilliam Blair Has Optimistic Outlook of APLS Q3 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities researchers at William Blair raised their Q3 2025 earnings estimates for shares of Apellis Pharmaceuticals in a report issued on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now forecasts that the company will postApril 6, 2025 | marketbeat.comWilliam Blair Has Positive Outlook for APLS Q3 EarningsApril 6, 2025 | americanbankingnews.comEquities Analysts Issue Forecasts for APLS Q2 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Analysts at William Blair boosted their Q2 2026 EPS estimates for Apellis Pharmaceuticals in a note issued to investors on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn $0.20 per shApril 5, 2025 | marketbeat.comCinctive Capital Management LP Takes Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Cinctive Capital Management LP acquired a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 86,991 shares of the company'April 5, 2025 | marketbeat.comVanguard Group Inc. Buys 230,450 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Vanguard Group Inc. lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 2.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,046,025 shares of the company's stock after purchasing an additional 230,450 shares duringApril 5, 2025 | marketbeat.comKLP Kapitalforvaltning AS Takes $504,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)KLP Kapitalforvaltning AS bought a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 15,800 shares of the company's stock, vaApril 5, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $31.00 at ScotiabankScotiabank upped their price objective on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a "sector perform" rating in a report on Wednesday.April 4, 2025 | marketbeat.comNational Bank of Canada FI Raises Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)National Bank of Canada FI lifted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 266,361.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,385,600 shares of the company's stock after purchasing an additional 1,April 4, 2025 | marketbeat.comPictet Asset Management Holding SA Has $11.10 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Pictet Asset Management Holding SA lifted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 16.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 347,854 shares of the coApril 4, 2025 | marketbeat.comWhat is William Blair's Estimate for APLS Q2 Earnings?April 4, 2025 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $31.00April 4, 2025 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Up 6.6% - Here's What HappenedApellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 6.6% - Here's What HappenedApril 3, 2025 | marketbeat.comRaymond James Financial Inc. Purchases New Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Raymond James Financial Inc. acquired a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 49,015 shares of the company's stock, valued at apprApril 3, 2025 | marketbeat.comBrokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Target Price at $45.53April 3, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS)April 2, 2025 | markets.businessinsider.comScotiabank Remains a Hold on Apellis Pharmaceuticals (APLS)April 2, 2025 | markets.businessinsider.comApellis announces FDA acceptance, priority review of sNDA for EMPAVELIApril 2, 2025 | markets.businessinsider.comApellis Pharmaceuticals is Now Oversold (APLS)April 2, 2025 | nasdaq.comApellis Pharmaceuticals (NASDAQ:APLS) Sets New 52-Week Low - Here's What HappenedApellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week Low - What's Next?April 1, 2025 | marketbeat.comApellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGNApril 1, 2025 | globenewswire.comPrudential Financial Inc. Sells 89,700 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Prudential Financial Inc. trimmed its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 31.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 198,060 shares of the company's stock after selling 89,700 shares during the period.April 1, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nineteen brokerages that are currently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a hold recoMarch 31, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Hits New 12-Month Low - What's Next?Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week Low - Here's WhyMarch 26, 2025 | marketbeat.comInteresting APLS Put And Call Options For May 16thMarch 26, 2025 | nasdaq.comIs Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street AnalystsMarch 25, 2025 | msn.comSwiss National Bank Sells 10,400 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Swiss National Bank lessened its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 6.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,700 shares of the company's sMarch 25, 2025 | marketbeat.comEvercore ISI Remains a Buy on Apellis Pharmaceuticals (APLS)March 25, 2025 | markets.businessinsider.comConnor Clark & Lunn Investment Management Ltd. Takes Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,478 shares of the company's stock, valMarch 23, 2025 | marketbeat.comCardurion Pharmaceuticals Appoints Karen Lewis as Chief People OfficerMarch 20, 2025 | finance.yahoo.comShort Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Grows By 20.1%Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 20,820,000 shares, a growth of 20.1% from the February 13th total of 17,340,000 shares. Based on an average daily volume of 1,990,000 shares, the days-to-cover ratio is currently 10.5 days. Approximately 18.0% of the shares of the company are sold short.March 19, 2025 | marketbeat.comCibc World Markets Corp Takes Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Cibc World Markets Corp purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,285,300 shares of the company's stock, valued at approximately $41,014,000. Cibc WMarch 17, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stake Boosted by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 4.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 996,748 shares of the company's stockMarch 17, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by AmundiAmundi boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 10,967.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 329,582 shares of the company's stock afteMarch 15, 2025 | marketbeat.comAlphaQuest LLC Buys 16,976 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)AlphaQuest LLC raised its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 8,083.8% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 17,186 shares of the company's stock after purchasing an additional 16,976 shares during the peMarch 13, 2025 | marketbeat.comVictory Capital Management Inc. Purchases 150,363 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Victory Capital Management Inc. grew its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 36.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 562,269 sharMarch 12, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Edgestream Partners L.P.Edgestream Partners L.P. boosted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 10.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,883 shares of the company's stock after buyingMarch 9, 2025 | marketbeat.comInsider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells 5,569 Shares of StockApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) General Counsel David O. Watson sold 5,569 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the sale, the general counsel now owns 138,730 shares of the company's stock, valued at approximately $3,482,123. This trade represents a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.March 7, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 5,569 SharesMarch 7, 2025 | insidertrades.comCandriam S.C.A. Has $17.22 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Candriam S.C.A. decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 20.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 539,602 shares of the company's stock after selling 140,456 shares during the periMarch 7, 2025 | marketbeat.comEquities Analysts Offer Predictions for APLS Q1 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at HC Wainwright raised their Q1 2025 EPS estimates for Apellis Pharmaceuticals in a research note issued on Monday, March 3rd. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.47) per shareMarch 6, 2025 | marketbeat.comWedbush Has Optimistic Outlook of APLS Q1 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Wedbush raised their Q1 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research note issued to investors on Monday, March 3rd. Wedbush analyst L. Chico now anticipates that the companyMarch 6, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nineteen research firms that are currently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating, ten have gMarch 6, 2025 | marketbeat.comApellis Pharmaceuticals: A Mixed BagMarch 5, 2025 | seekingalpha.comApellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan AnalystMarch 5, 2025 | benzinga.comApellis Pharmaceuticals (NASDAQ:APLS) Given New $54.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. lifted their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a research report on Tuesday.March 5, 2025 | marketbeat.com Remove Ads Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Media Mentions By Week APLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼1.090.92▲Average Medical News Sentiment APLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼238▲APLS Articles Average Week Remove Ads Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News VTRS News QGEN News ASND News ROIV News LNTH News TGTX News RVMD News BBIO News LEGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersBITCOINYou're not going to believe this. There's a bizarre new way to make money from crypto... ...and it's not...Awesomely, LLC | SponsoredWhy crypto may be the best way to play this chaotic market …Wall Street is in chaos … Over $6 trillion was wiped … in just two days. But something else was happenin...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredOil Surge Predicted... But Are You Ready?Do you own oil and gas stocks? Or are you thinking about buying some? But it's NOT oil stocks, futures, or ...The Oxford Club | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APLS Stock Free APLS Stock Alerts